Cyclacel Pharmaceuticals, Inc. – NASDAQ:CYCCP
Cyclacel Pharmaceuticals stock price today
Cyclacel Pharmaceuticals stock price monthly change
Cyclacel Pharmaceuticals stock price quarterly change
Cyclacel Pharmaceuticals stock price yearly change
Cyclacel Pharmaceuticals key metrics
Market Cap | 2.08M |
Enterprise value | 7.86M |
P/E | -5.53 |
EV/Sales | N/A |
EV/EBITDA | -0.27 |
Price/Sales | N/A |
Price/Book | 8.65 |
PEG ratio | -0.21 |
EPS | -22.18 |
Revenue | 449K |
EBITDA | -25.82M |
Income | -19.76M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -5751.45% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCyclacel Pharmaceuticals stock price history
Cyclacel Pharmaceuticals stock forecast
Cyclacel Pharmaceuticals financial statements
| Jun 2023 | 373K | -5.44M | -1460.59% |
|---|---|---|---|
| Sep 2023 | 16K | -6.09M | -38106.25% |
| Dec 2023 | 31K | -5.27M | -17003.23% |
| Mar 2024 | 29K | -2.94M | -10158.62% |
Paying a dividend while loss making.
| Payout ratio | -0.88% |
|---|
| 2019 | 1.84% |
|---|---|
| 2020 | 0.71% |
| 2021 | 0.58% |
| 2022 | 3.06% |
| 2023 | 8.85% |
| Jun 2023 | 16442000 | 6.81M | 41.43% |
|---|---|---|---|
| Sep 2023 | 12432000 | 8.08M | 65% |
| Dec 2023 | 8805000 | 8.19M | 93.11% |
| Mar 2024 | 6165000 | 8.37M | 135.78% |
| Jun 2023 | -1.30M | 0 | -51K |
|---|---|---|---|
| Sep 2023 | -4.03M | 4.21M | -50K |
| Dec 2023 | -3.91M | -4.21M | 999K |
| Mar 2024 | -483K | 0 | -79K |
Cyclacel Pharmaceuticals alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
Cyclacel Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 1000 | 0 |
| Nov 2021 | 4000 | 12 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BARKER SAM L director | Common Stock | 12 | $3.57 | $43 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Common Stock | 4,000 | $4.5 | $18,000 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Common Stock | 4,000 | $4.5 | $18,000 | ||
Purchase | BARKER SAM L director | Common Stock | 1,000 | $5 | $5,000 | ||
Purchase | EASTERN CAPITAL LTD | Common Stock | 850,000 | $2 | $1,700,000 | ||
Purchase | EASTERN CAPITAL LTD | Warrant | 1 | $2 | $2 | ||
Purchase | TANG KEVIN C | Common Stock | 134,200 | $4.34 | $582,025 |
-
What's the price of Cyclacel Pharmaceuticals stock today?
One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $5.2.
-
When is Cyclacel Pharmaceuticals's next earnings date?
Unfortunately, Cyclacel Pharmaceuticals's (CYCCP) next earnings date is currently unknown.
-
Does Cyclacel Pharmaceuticals pay dividends?
Yes, Cyclacel Pharmaceuticals pays dividends and its trailing 12-month yield is 5.93% with -1% payout ratio.It means that the company is paying a dividend while loss making. The last Cyclacel Pharmaceuticals stock dividend of $0.15 was paid on 1 Feb 2022.
-
How much money does Cyclacel Pharmaceuticals make?
Cyclacel Pharmaceuticals has a market capitalization of 2.08M.
-
What is Cyclacel Pharmaceuticals's stock symbol?
Cyclacel Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CYCCP".
-
What is Cyclacel Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cyclacel Pharmaceuticals?
Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cyclacel Pharmaceuticals's key executives?
Cyclacel Pharmaceuticals's management team includes the following people:
- Mr. Spiro George Rombotis Pres, Chief Executive Officer & Executive Director(age: 66, pay: $772,640)
- Mr. Paul McBarron Executive Vice President, Chief Financial Officer, Chief Operating Officer, Sec. & Executive Director(age: 64, pay: $391,910)
- Dr. Mark H. Kirschbaum M.D. Senior Vice President & Chief Medical Officer(age: 64, pay: $354,730)
-
How many employees does Cyclacel Pharmaceuticals have?
As Jul 2024, Cyclacel Pharmaceuticals employs 12 workers.
-
When Cyclacel Pharmaceuticals went public?
Cyclacel Pharmaceuticals, Inc. is publicly traded company for more then 19 years since IPO on 30 Nov 2005.
-
What is Cyclacel Pharmaceuticals's official website?
The official website for Cyclacel Pharmaceuticals is cyclacel.com.
-
Where are Cyclacel Pharmaceuticals's headquarters?
Cyclacel Pharmaceuticals is headquartered at 200 Connell Drive, Berkeley Heights, NJ.
-
How can i contact Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals's mailing address is 200 Connell Drive, Berkeley Heights, NJ and company can be reached via phone at +90 85177330.
Cyclacel Pharmaceuticals company profile:
Cyclacel Pharmaceuticals, Inc.
cyclacel.comNASDAQ
12
Biotechnology
Healthcare
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Berkeley Heights, NJ 07922
CIK: 0001130166
ISIN: US23254L2079
CUSIP: 23254L207
